Fig. 4From: Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong KongCost-effectiveness plane for pembrolizumab vs. DTIC. Higher threshold = 3 * GDP per capita; Lower threshold = 1 * GDP per capitaBack to article page